EYPT EyePoint Pharmaceuticals 8-K2021EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
11 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
EYPT 8-K Filings
- 11 Jan 21 EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
- 4 Jan 21 EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
- 18 Dec 20 EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
- 8 Dec 20 EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…